Learn how often treatment with BENDEKA is given

You may or may not have already had an infusion with BENDEKA. Use this calendar tool to help you find out how often you’ll be given BENDEKA.

  • *What type of cancer do you have?

    *Start of treatment cycle

    Month
    January
    February
    March
    April
    May
    June
    July
    August
    September
    October
    November
    December
    Day
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    Year

    *Pick the number of months you want to see:

    No. of months
    1 month
    2 months
    3 months
    4 months
    5 months
    6 months

    *fields are required

    Talk to your doctor about exact dates for your next infusions. These dates are for information purposes only. Your doctor may change your infusion dates. If your doctor changes your dates, you can change the remaining dates here. You may not need all treatment cycles in a course of BENDEKA.

    • Cycles
    • Day 1
    • Day 2
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       
    •  
    •  
       

Your dose may change

Not all patients react to medications the same way, so it may be necessary for your doctor to make changes to the dose of BENDEKA to find out what is right for you or even to stop treatment. Changing the dose or delaying treatment may be necessary if you are experiencing side effects. The most important goal is to find the treatment approach that will help you achieve the best results possible. Your doctor may change, delay, or even stop your treatment.

MORE
LESS

Approved Use

BENDEKA is indicated for the treatment of patients with

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

  • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

BENDEKA (bendamustine HCl) injection is not right for everyone, including patients with a known allergic response to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol.

BENDEKA may cause serious side effects including: low blood cell counts, infections or recurrence of infections, unexpected responses to BENDEKA when placed in your blood, sudden and severe allergic responses, kidney failure due to fast breakdown of cancer cells, other cancers, and leaking of BENDEKA out of your vein and into your surrounding skin. Some of these side effects, such as low blood counts, infections, liver injury, and severe allergic skin responses (when bendamustine HCl was given alone and in combination with other anticancer medications or allopurinol), have caused death.

Tell your doctor if you have any side effects including: rash, facial swelling, or difficulty breathing during or soon after your infusion with BENDEKA injection. These are signs of an allergic reaction. You also should tell your doctor if you have shortness of breath, significant fatigue, bleeding, bruising, fever, or other signs of infection. Also, tell your doctor if you experience nausea, vomiting, diarrhea, loss of appetite, or a yellow skin tone. In addition, your doctor will perform blood tests to see if you have low blood counts. These are lower-than-normal numbers of red blood cells, white blood cells, or platelets.

Some serious side effects may require changes in therapy, such as lowering the amount of BENDEKA given, stopping the use of BENDEKA, or waiting longer than expected between doses of BENDEKA.

BENDEKA may cause fetal harm if taken while pregnant. Women should avoid becoming pregnant or nursing while receiving BENDEKA.

Non–blood-related side effects may occur including: fever, nausea, and vomiting, diarrhea, constipation, loss of appetite, cough, headache, weight loss, difficulty breathing, rash, and mouth irritation.

Blood-related side effects may occur including: low red blood cells (oxygen-carrying cells), low platelets (blood-clotting cells), and decreased number of three different types of white blood cells (infection-fighting cells).

These are not all of the possible side effects of BENDEKA. For more information ask your healthcare provider.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information about BENDEKA, ask your doctor, or call 1-800-896-5855.

This information does not take the place of talking with your doctor for medical advice about your condition or treatment.

Please read the Full Prescribing Information.

BENDEKA® is a registered trademark of Cephalon, Inc.
©2017 Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.
All rights reserved. BEN-40430 June 2017.

The information presented on this Web site is intended for US residents only.

MORE
LESS

Approved Use

BENDEKA is indicated for the treatment of patients with

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

  • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

BENDEKA (bendamustine HCl) injection is not right for everyone, including patients with a known allergic response to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol.

BENDEKA may cause serious side effects including: low blood cell counts, infections or recurrence of infections, unexpected responses to BENDEKA when placed in your blood, sudden and severe allergic responses, kidney failure due to fast breakdown of cancer cells, other cancers, and leaking of BENDEKA out of your vein and into your surrounding skin. Some of these side effects, such as low blood counts, infections, liver injury, and severe allergic skin responses (when bendamustine HCl was given alone and in combination with other anticancer medications or allopurinol), have caused death.

Tell your doctor if you have any side effects including: rash, facial swelling, or difficulty breathing during or soon after your infusion with BENDEKA injection. These are signs of an allergic reaction. You also should tell your doctor if you have shortness of breath, significant fatigue, bleeding, bruising, fever, or other signs of infection. Also, tell your doctor if you experience nausea, vomiting, diarrhea, loss of appetite, or a yellow skin tone. In addition, your doctor will perform blood tests to see if you have low blood counts. These are lower-than-normal numbers of red blood cells, white blood cells, or platelets.

Some serious side effects may require changes in therapy, such as lowering the amount of BENDEKA given, stopping the use of BENDEKA, or waiting longer than expected between doses of BENDEKA.

BENDEKA may cause fetal harm if taken while pregnant. Women should avoid becoming pregnant or nursing while receiving BENDEKA.

Non–blood-related side effects may occur including: fever, nausea, and vomiting, diarrhea, constipation, loss of appetite, cough, headache, weight loss, difficulty breathing, rash, and mouth irritation.

Blood-related side effects may occur including: low red blood cells (oxygen-carrying cells), low platelets (blood-clotting cells), and decreased number of three different types of white blood cells (infection-fighting cells).

These are not all of the possible side effects of BENDEKA. For more information ask your healthcare provider.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information about BENDEKA, ask your doctor, or call 1-800-896-5855.

This information does not take the place of talking with your doctor for medical advice about your condition or treatment.

Please read the Full Prescribing Information.